Drug interactions of 5-fluorouracil with either cisplatin or lobaplatin - A new, clinically active platinum analog in established human cancer cell lines

Anti-Cancer Drugs

Volumn 8, Issue 4, 1997, Pages 391-395

  Harstrick, A ^a   Vanhoefer, U ^a   Heidemann, A ^a   Druyen, H ^a   Wilke, H ^a   Seeber, S ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

5 Fluorouracil; Cisplatin; Lobaplatin

Indexed keywords

CISPLATIN; D 19644; FLUOROURACIL; LOBAPLATIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG INTERACTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR CELL LINE;

EID: 0030974774     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199704000-00013     Document Type: Article

References (18)

1. Reed E. Platinum analogs. In: DeVita V, Hellman S, Rosenberg SA, eds. Cancer, principles and practice of oncology, 4th edn. Philadelphia; Lippincott 1993: 390-9.
2. Scanlon KJ, Newman EM, Lu Y, Priest DG. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 1986; 83: 8923-5.
3. Shirasaka T, Shimamoto Y, Ohshimo H, Saito H, Fukushima M. Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo. Cancer Chemother Pharmacol 1993; 32: 167-72.
4. Kish JA, Ensley JF, Jacobs J, et al. A randomized trial of cisplatin and 5-FU infusion and cisplatin and 5-FU bolus for recurrent and advanced squamous cancer of the head and neck. Cancer 1985; 56: 2740-4.
5. Amrein PC, Weitzman SA. Treatment of squamous cell carcinoma of the head and neck with cisplatin and 5-fluorouracil. J Clin Oncol 1985; 3: 1632-9.
6. Gietema JA, Veldhuis GJ, Guchelaar HJ, et al. Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer. Br J Cancer 1995; 71: 1302-7.
7. Schmoll HJ, Köhne CH, Papageorgiou E, et al. Single agent lobaplatin is active in patients with oesophageal squamous cell carcinoma: a phase II evaluation. Am Soc Clin Oncol 1995; 14: 201.
8. Harstrick A, Schmoll HJ, Scharnofske M, Hapke G, Reile D, Poliwoda H. High preclinical activity of a new platinum analogue, lobaplatin (1,2-diamminomethylcyclobutane-platinum(II)lactate), in cisplatin sensitive and resistant human testicular ovarian, and gastric carcinoma cell lines. Cancer Chemother Pharmacol 1993; 33: 43-7.
9. Fiebig HH, Mross K, Henß H, et al. Phase I clinical trial of lobaplatin (D-19466) after intravenous bolus injection. Onkologie 1994; 17: 142-8.
10. Fiebig HH, Henß H, v. Pawel I, et al. Phase II clinical trial of lobaplatin in pretreated patients with small cell lung cancer. Onkologie 1996; 19: 328-32.
11. Skehan P, Storeng R, Scudiero D. New colorimetric cytotoxicity assay for anticancer drug screening. J Natl Cancer Inst 1990; 82: 1107-12.
12. Berenbaum MC. What is synergy? Pharmacol Rev 1989; 41: 93-140.
13. Aschele C, Sobrero A, Faderan MA, Bertino J. Novel mechanisms of resistance to 5-fluorouracil in human colon cancer (HCT8) sublines following exposure to two different, clinically relevant dose schedules. Cancer Res 1992; 52: 1855-64.
14. Wang FS, Aschele C, Sobrero A, Chang YM, Bertino JR. Decreased folylpolyglutamate synthetase expression, a novel mechanism of fluorouracil resistance. Cancer Res 1993; 53: 3667-70.
15. Mon A, Bertoglio S, Guglielmi A, et al. Activity of continuous infusion 5-fluorouracil in patients with advanced colorectal cancer, clinically resistant to bolus 5-fluorouracil. Cancer Chemother Pharmacol 1993; 33: 179-80.
16. Weh HJ, Wilke H, Dierlamm J, et al. Weekly therapy with folinic acid and high dose fluorouracil 24-hour infusion in pretreated patients with metastatic colorectal carcinoma. Ann Oncol 1994; 5: 233-7.
17. Vanhoefer U, Wilke H, Weh HJ, et al. Weekly high-dose 5-fluorouracil and folinic acid as salvage treatment in advanced gastric cancer. Ann Oncol 1994; 5: 850-1.
18. Lokich JJ, Ahlgren JD, Gullo JJ, Phillips JA, Fryer JG. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma. J Clin Oncol 1989; 7: 425-32.